Effect of Intravitreal Ranibizumab in the Treatment of Peripapillary Choroidal Neovascularisation

Table 1

Patient characteristics and treatment results. (F: female; M: male). (Central retinal thickness).

Patient number	Sex	Age years	Diagnosis	Onset ETDRS	Current ETDRS	Number of injections	Onset CRT	Current CRT	Follow-up months	Current status
1	F	80	Idiopathic	77	78	10	302	235	22	Continuous treatment
2	M	74	Idiopathic	65	76	9	291	211	21	Continuous treatment
3	F	70	Idiopathic	59	83	3	461	210	14	Inactive
4	F	81	AMD	65	45	9	486	140	27	Continuous treatment
5	F	87	Idiopathic	70	85	3	274	245	18	Inactive
6	F	76	Idiopathic	35	46	3	400	292	23	Inactive
7	F	70	Idiopathic	85	90	9	280	280	17	Inactive
8	F	81	Idiopathic	65	70	6	615	543	9	Continuous treatment
9	M	76	AMD	65	73	6	348	280	15	Inactive
10	M	76	AMD	28	32	5	500	384	9	Inactive
11	M	28	Idiopathic	26	47	6	350	322	9	Inactive
12	M	81	Idiopathic	72	63	5	307	250	9	Continuous treatment